Free practice quiz
CTCS Prep Course (CTCS): free quiz
10 questions from the program. See your score right away, then unlock the explanation of every answer.
- Question 1 of 10
A tobacco treatment specialist is building CTCS study notes for a case involving nicotine patch 21 mg transdermal once daily and nicotine gum 2 mg buccal as needed for cravings. Official detailed CTCS blueprint information is limited. Which mapping approach best stays within exam-prep and professional-scope boundaries?
B is correct: when official detail is sparse, inferred domains should be transparent and anchored to recognized tobacco-treatment competencies. C is tempting because training materials overlap, but it falsely treats inference as official CPS policy. A overweights medication; pharmacotherapy literacy matters, but CTCS preparation also includes assessment, counseling, relapse prevention, and ethics. D confuses scope limits with content exclusion; specialists may educate and coordinate about approved medications such as nicotine replacement while not prescribing unless authorized.
- Question 2 of 10
A client in cessation counseling says their clinician prescribed bupropion SR 150 mg by mouth twice daily and nicotine patch 21 mg transdermal daily. Today, the client reports starting phenelzine 15 mg by mouth three times daily from another clinician. As a tobacco treatment specialist, which response best fits your role?
C is correct. Bupropion affects norepinephrine and dopamine; MAOIs such as phenelzine increase monoamine activity, and FDA labeling contraindicates co-use because of hypertensive reactions. D is tempting because patch plus bupropion can be evidence-based, but it misses the interaction. B is a dose-adjustment trap: changing the regimen is outside CTCS scope and does not resolve the contraindication. A is tempting because varenicline is first-line, but initiating or switching medication requires an authorized clinician. The CTCS role is to educate, clarify/escalate, document, and continue counseling.
- Question 3 of 10
As a tobacco treatment specialist, you are documenting product use for a client who smokes cigarettes daily, uses hookah on weekends, keeps moist snuff at work, and vapes a nicotine-containing e-cigarette when smoking is not allowed. Which classification best captures this pattern?
Option A is correct: the client uses more than two products across major categories—combustible cigarettes and hookah, smokeless moist snuff, and an electronic nicotine delivery system. Option B is tempting because cigarettes plus vaping is common dual use, but it ignores hookah and snuff. Option D is tempting because combustible products carry substantial toxicant exposure, but it omits smokeless and electronic use. Option C is incorrect because many e-cigarettes contain nicotine, and assessment should explicitly document nicotine-containing versus non-nicotine products. CTCS practice emphasizes precise, nonjudgmental assessment of all tobacco and nicotine products.
- Question 4 of 10
A CTCS in a pharmacist-collaborative cessation clinic counsels Jordan, who uses nicotine polacrilex gum 2 mg by buccal route every 1–2 hours as needed while smoking 10 cigarettes/day. Jordan says cigarettes feel “stronger” than gum despite similar cravings later. Which counseling point best explains the difference in reinforcement?
C is correct: pulmonary absorption from cigarettes produces rapid arterial nicotine delivery to the brain, increasing reinforcement. D is tempting because patches provide steady nicotine, but transdermal delivery is slow and less spike-like. B is a dose trap: 4 mg gum may improve replacement for more dependent users, but buccal absorption remains slower than inhaled smoke. A is an administration-interaction trap: acidic drinks can reduce gum absorption, but avoiding them does not make gum cigarette-fast. Review Nicotine Absorption and Delivery — focus on route, speed, and reinforcement.
- Question 5 of 10
A client quit cigarettes yesterday and is using nicotine patch 21 mg transdermal once daily as directed by the clinic prescriber. During a CTCS follow-up, the client reports feeling edgy, trouble sleeping, poor concentration, eating more, and sudden urges to smoke that come and go. Which counseling response best normalizes these symptoms while supporting the quit plan?
Option A is correct: irritability, anxiety, restlessness, insomnia, poor concentration, increased appetite, mood changes, and fluctuating craving are common after tobacco cessation, even when nicotine replacement reduces withdrawal. Option B is tempting because medication fit matters, but a CTCS should not independently alter dosing; clarify use and coordinate with the prescriber for severe or persistent symptoms. Option D is incorrect because withdrawal is expected and does not mean failure. Option C is incorrect because craving and withdrawal can persist or recur with triggers. Supportive counseling should normalize symptoms, teach coping skills, monitor safety, and arrange follow-up.
- Question 6 of 10
A client who smokes 20 cigarettes/day is using nicotine transdermal patch 21 mg once daily as part of a quit plan. They say, “I may just switch to light cigarettes because the smoke is what relaxes me.” Within tobacco treatment specialist scope, which counseling response best addresses combustible tobacco harm?
Option B is correct: burning tobacco generates toxicants that cause cardiovascular disease, COPD, cancer, and secondhand-smoke harm; quitting lowers risk, though timelines vary. A is tempting because “light” sounds lower exposure, but compensatory smoking prevents meaningful risk reduction. D is tempting because nicotine replacement treats withdrawal, but it does not make continued smoke exposure safe. C is tempting for cravings, but a specialist should not independently change patch dosing; medication concerns should be coordinated with an authorized clinician or pharmacist.
- Question 7 of 10
During intake at a community cessation program, a tobacco treatment specialist is updating the standard screening form for all adult clients. Which wording best supports universal tobacco and nicotine screening?
Universal screening should ask every client about current and recent tobacco or nicotine use using clear, neutral, inclusive language. Option C includes multiple product types and avoids judgment, supporting consistent documentation of current, former, and recent use. A is leading and may discourage disclosure. C is shaming and not client-centered. A limits screening to cigarettes and to clients ready to quit, missing other nicotine products and readiness stages.
- Question 8 of 10
During CTCS intake, a client asks about using nicotine patch 21 mg transdermally once daily and nicotine lozenge 2 mg orally every 1–2 hours as needed per clinician-approved protocol. You are assessing dependence before reinforcing the quit plan. Which reported pattern is the strongest indicator of higher nicotine dependence severity?
Time to first tobacco use is a validated dependence marker; use within 5 minutes of waking, especially with night waking to smoke, suggests high physiologic dependence and higher nicotine exposure. C is tempting because driving is a trigger, but cue-specific use alone is less severe. A includes multiple nicotine products, which can increase exposure, but weekend-only use suggests lower daily dependence. A describes a conditioned trigger, not a global severity marker. The CTCS should document these patterns, educate on approved medication use within protocol, and coordinate with a clinician for medication changes.
- Question 9 of 10
A client smokes 15 cigarettes/day and reports a prior quit attempt using nicotine patch 21 mg transdermally once daily, stopped after 4 days. The client says, “I know smoking is harmful, but I’m not ready to set a quit date. Maybe in a few months.” As a tobacco treatment specialist, what is the best next response?
D is correct: readiness can change, so assessing interest, intention, timeline, confidence, and barriers using motivational interviewing preserves autonomy. A is tempting because quit dates and pharmacotherapy help prepared clients, but forcing a quit date prematurely is inconsistent with stage-matched care. C respects autonomy but misses an opportunity for the 5 R’s and continued engagement. B addresses a real prior medication barrier, but it narrows the encounter to pharmacotherapy and may move beyond CTCS scope if framed as medication direction rather than education/referral.
- Question 10 of 10
A fictional client reports smoking cigarettes daily and using a 21 mg nicotine patch transdermally once daily from a prior quit attempt. As a tobacco treatment specialist completing baseline documentation before counseling, which entry best captures essential assessment elements?
Option D is correct because baseline assessment should support a tailored quit plan: tobacco/nicotine products, frequency, dependence, prior attempts, motivation, goals, safety concerns, referral needs, and follow-up preferences. Option B is tempting because cigarettes per day matters, but it misses quit history and safety/referral data. Option B includes motivation but oversteps if the specialist independently changes medication and omits product/follow-up details. Option C is tempting due to the patch context, but medication documentation alone is insufficient. CTCS practice should educate and coordinate, not prescribe or alter regimens unless separately authorized.
See why each answer is right or wrong
Enter your email to unlock the explanation of every question, free.